Results 21 to 30 of about 5,411 (177)

Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background A decline in skeletal muscle mass and function known as skeletal muscle sarcopenia is an inevitable consequence of aging. Sarcopenia is a major cause of decreased muscle strength, physical frailty and increased muscle fatigability ...
Chhanda Bose, Judit Megyesi, Oleg Karaduta, Sharda P. Singh, Sundararaman Swaminathan, Sudhir V. Shah   +5 more
doaj   +2 more sources

Efficacy of combination chelation with deferasirox and deferiprone in children with beta-thalassemia major: an audit from a unit in the developing world. [PDF]

Clin Exp Med
James V, Prakash A.
europepmc   +3 more sources

Microscale Thermophoresis and Molecular Modelling to Explore the Chelating Drug Transportation in the Milk to Infant

Molecules, 2022
The microscale thermophoresis (MST) technique was utilized to investigate lactoferrin–drug interaction with the iron chelator, deferiprone, using label-free system. MST depends on the intrinsic fluorescence of one interacting partner.
Mufarreh Asmari, Muhammad Waqas, Adel Ehab Ibrahim, Sobia Ahsan Halim, Ajmal Khan, Ahmed Al-Harrasi, Hermann Wätzig, Sami El Deeb   +7 more
doaj   +1 more source

Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE

Drugs in Context, 2022
Background: Hyperfunctional platelets play important roles in thromboembolism in patients with β-thalassaemia/ haemoglobin E (β-thal/HbE). Our previous study revealed ex vivo inhibitory effects of deferiprone on normal platelets.
Ngan Thi Tran, Pranee Sutcharitchan, Jindaporn Janprasit, Ponlapat Rojnuckarin, Noppawan Phumala Morales, Rataya Luechapudiporn   +5 more
doaj   +1 more source

Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice

eLife, 2023
Myelodysplastic syndrome (MDS) is a heterogeneous group of bone marrow stem cell disorders characterized by ineffective hematopoiesis and cytopenias, most commonly anemia.
Wenbin An, Maria Feola, Maayan Levy, Srinivas Aluri, Marc Ruiz-Martinez, Ashwin Sridharan, Eitan Fibach, Xiaofan Zhu, Amit Verma, Yelena Ginzburg   +9 more
doaj   +1 more source

Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children [PDF]

Pharmacology and Clinical Pharmacy Research, 2016
Thalassemia major (TM) is an inherited disease caused by defective or absent of hemoglobin chain synthesis. Regular chelation therapy is necessary to reduce excess iron in several organs of TM patients.
Asti Y. Rindarwati, Ajeng Diantini, keri Lestari   +2 more
doaj   +1 more source

Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition

Platelets, 2020
Thalassemia patients are susceptible to both iron overload and thromboembolism. Deferiprone is an iron chelator that shows an antiplatelet activity and thus may alleviate platelet hyperactivation in thalassemia.
Ngan Thi Tran, Benjaporn Akkawat, Noppawan Phumala Morales, Ponlapat Rojnuckarin, Rataya Luechapudiporn   +4 more
doaj   +1 more source

Measurement and correlation of solubility data for deferiprone in propylene glycol and 2-propanol at different temperatures

Heliyon, 2023
This investigation dealt with the thermodynamic properties, saturated solubility values, and solvation behavior of deferiprone as an oral iron chelator agent in non-aqueous mixtures of propylene glycol and 2-propanol using experimental measurements and ...
Homa Rezaei, Elaheh Rahimpour, Fleming Martinez, Abolghasem Jouyban   +3 more
doaj   +1 more source

Deferiprone ameliorates cisplatin induced peripheral neurotoxicity via ferritinophagy adjustment. [PDF]

Sci Rep
Seddiek H, Hanna M, Hamoud AEM, Elbaset MA, Akabawy AMA, Kotb MZ, Khalifa MM.   +6 more
europepmc   +3 more sources

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case

Indian Journal of Radiology and Imaging, 2009
Arthropathy is a well known side effect of the iron chelator deferiprone (L1); however, the imaging findings in deferiprone-induced arthropathy are not well known.
Gyan Chand, Veena Chowdhury, A Manchanda, Sapna Singh   +3 more
doaj   +1 more source